Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/149576
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Blasco-Benito, Sandra | - |
dc.contributor.author | Moreno Guillén, Estefanía | - |
dc.contributor.author | Seijo-Vila, Marta | - |
dc.contributor.author | Tundidor, Isabel | - |
dc.contributor.author | Andradas, Clara | - |
dc.contributor.author | Caffarel, María M. | - |
dc.contributor.author | Caro-Villalobos, Miriam | - |
dc.contributor.author | Urigüen, Leyre | - |
dc.contributor.author | Diez-Alarcia, Rebeca | - |
dc.contributor.author | Moreno-Bueno, Gema | - |
dc.contributor.author | Hernández, Lucía | - |
dc.contributor.author | Manso, Luis | - |
dc.contributor.author | Homar Ruano, Patricia C. | - |
dc.contributor.author | McCormick, Peter J. | - |
dc.contributor.author | Bibic, Lucka | - |
dc.contributor.author | Bernadó Morales, Cristina | - |
dc.contributor.author | Arribas, Joaquín V. (Vicente) | - |
dc.contributor.author | Canals Buj, Meritxell | - |
dc.contributor.author | Casadó, Vicent | - |
dc.contributor.author | Canela Campos, Enric I. | - |
dc.contributor.author | Guzmán, Manuel | - |
dc.contributor.author | Pérez-Gómez, Eduardo | - |
dc.contributor.author | Sánchez Mora, Cristina | - |
dc.date.accessioned | 2020-02-07T14:50:46Z | - |
dc.date.available | 2020-02-07T14:50:46Z | - |
dc.date.issued | 2019-02-26 | - |
dc.identifier.issn | 0027-8424 | - |
dc.identifier.uri | http://hdl.handle.net/2445/149576 | - |
dc.description.abstract | There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB2R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2-CB2R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | National Academy of Sciences | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1073/pnas.1815034116 | - |
dc.relation.ispartof | Proceedings of the National Academy of Sciences of the United States of America - PNAS, 2019, vol. 116, num. 9, p. 3863-3872 | - |
dc.relation.uri | https://doi.org/10.1073/pnas.1815034116 | - |
dc.rights | (c) Blasco-Benito, Sandra et al., 2019 | - |
dc.source | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.other | Breast cancer | - |
dc.title | Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 685639 | - |
dc.date.updated | 2020-02-07T14:50:46Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 24023743 | - |
dc.identifier.pmid | 30733293 | - |
Appears in Collections: | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
685639.pdf | 2.52 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.